Fusion Antibodies PLC (FAB) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.792x

Based on the latest financial reports, Fusion Antibodies PLC (FAB) has a cash flow conversion efficiency ratio of -0.792x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-575.00K ≈ $-69.96 USD) by net assets (GBX726.00K ≈ $88.33 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Fusion Antibodies PLC market cap and net worth for the company's overall valuation and market capitalisation.

Fusion Antibodies PLC - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Fusion Antibodies PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Fusion Antibodies PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Fusion Antibodies PLC ranked by their cash flow conversion efficiency. Explore Fusion Antibodies PLC cash earnings quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Tavistock Investments Plc LSE:TAVI	-0.096x
I.Ceram SA PA:ALICR	0.094x
Cambridge Cognition Holdings Plc LSE:COG	-0.196x
Bumhan Fuel Cell Co. Ltd. KQ:382900	N/A
Virgin Wines UK PLC LSE:VINO	-0.137x
LMS Capital Plc LSE:LMS	-0.042x
Lexington Gold Ltd LSE:LEX	-0.028x
Meyer Burger Tech AG SW:MBTN	-0.961x

Annual Cash Flow Conversion Efficiency for Fusion Antibodies PLC (2015–2025)

The table below shows the annual cash flow conversion efficiency of Fusion Antibodies PLC from 2015 to 2025. View Fusion Antibodies PLC stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	GBX669.00K ≈ $81.40	GBX-1.36 Million ≈ $-165.96	-2.039x	-106.65%
2024-03-31	GBX1.79 Million ≈ $218.16	GBX-1.77 Million ≈ $-215.24	-0.987x	+36.87%
2023-03-31	GBX1.12 Million ≈ $136.64	GBX-1.75 Million ≈ $-213.53	-1.563x	-1644.63%
2022-03-31	GBX3.68 Million ≈ $448.24	GBX-330.00K ≈ $-40.15	-0.090x	+63.06%
2021-03-31	GBX4.75 Million ≈ $577.57	GBX-1.15 Million ≈ $-140.04	-0.242x	-602.87%
2020-03-31	GBX4.81 Million ≈ $585.48	GBX-166.00K ≈ $-20.20	-0.034x	+83.18%
2019-03-31	GBX5.35 Million ≈ $651.44	GBX-1.10 Million ≈ $-133.64	-0.205x	-1847.36%
2018-03-31	GBX6.58 Million ≈ $800.00	GBX77.19K ≈ $9.39	0.012x	+153.59%
2017-03-31	GBX1.71 Million ≈ $207.56	GBX-37.37K ≈ $-4.55	-0.022x	-109.21%
2016-03-31	GBX1.46 Million ≈ $177.28	GBX346.57K ≈ $42.17	0.238x	+122.12%
2015-03-31	GBX169.29K ≈ $20.60	GBX-182.05K ≈ $-22.15	-1.075x	--

About Fusion Antibodies PLC

LSE:FAB UK Biotechnology

Market Cap

$154.88K

GBX1.27 Billion GBX

Market Cap Rank

#31392 Global

#1058 in UK

Share Price

GBX11.20

Change (1 day)

-0.44%

52-Week Range

GBX9.25 - GBX19.25

All Time High

GBX213.00